REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 382 participants.

Also called NCT03618095

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 382 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03618095
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03618095. Non-randomized; no masking; primary purpose treatment. Start 2019-01-14 (actual); primary completion 2021-03-30 (actual). Results posted on 2022-12-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects
Acronym
REPRISE IV
Condition
Aortic Valve Stenosis
Intervention (Device)
LOTUS Edge Valve System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct03618095
Content hash
74b61e5d76fb03b4a739d83764c00ef96891f0bafc30a73639ef66a8c8a54a5e